A Phase 1 interventional study of DWP14012 and DWC202201 in Drug Drug Interaction, sponsored by Daewoong Pharmaceutical Co. LTD.. Status unknown at 1 site in Korea, Republic of. Open to participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-13.
Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A randomized, open-label, three-period, three-sequence, multiple dosing crossover, phase 1 clinical trial to evaluate the effect of DWP14012 on the pharmacokinetics of DWC202201 after co-administration of DWP14012 and DWC202201 in healthy subjects
Daewoong Pharmaceutical Co. LTD. is the lead sponsor of 200 studies on the registry; 33 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects with a body weight ≥ 50.0 kg to ≤ 90.0 kg with a (BMI) of ≥ 18.0 kg/m2 to ≤ 27.0 kg/m2 at screening
※ BMI (kg/m2) = body weight (kg)/[height (m)]2
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
* Treatment A: DWC202201 40 mg qd for 7 days * Treatment B: DWP14012 40 mg qd for 7 days, followed by DWC202201 40 mg qd + DWP14012 40 mg qd for 7 days * Treatment C: DWP14012 40 mg qd for 14 days
Drug: DWP14012 · Drug: DWC202201
* Treatment C: DWP14012 40 mg qd for 14 days * Treatment A: DWC202201 40 mg qd for 7 days * Treatment B: DWP14012 40 mg qd for 7 days, followed by DWC202201 40 mg qd + DWP14012 40 mg qd for 7 days
Drug: DWP14012 · Drug: DWC202201
* Treatment B: DWP14012 40 mg qd for 7 days, followed by DWC202201 40 mg qd + DWP14012 40 mg qd for 7 days * Treatment C: DWP14012 40 mg qd for 14 days * Treatment A: DWC202201 40 mg qd for 7 days
Drug: DWP14012 · Drug: DWC202201
Potassium-competitive acid blocker
Atorvastatin Calcium Trihydrate
Atorvastatin Peak Plasma Concentration at steady state (Cmax,ss) after DWC202201 multiple dosing
Time frame: [Time Frame: up to 64 days]
Atorvastatin Area under the plasma concentration versus time curve at steady state (AUCinf, ss) after DWC202201 multiple dosing
Time frame: [Time Frame: up to 64 days]
Atorvastatin Area under the plasma concentration extrapolated to infinity at steady state (AUC,ss) after DWC202201 multiple dosing
Time frame: [Time Frame: up to 64 days]
Atorvastatin Time to peak drug concentration at staedy state (Tmax, ss) after DWC202201 multiple dosing
Time frame: [Time Frame: up to 64 days]
Atorvastatin Terminal Half-life at steady state (T1/2,ss) after DWC202201 multiple dosing
Time frame: [Time Frame: up to 64 days]
Atorvastatin Apparent total body clearance at steady state (CLss/F) after DWC202201 multiple dosing
Time frame: [Time Frame: up to 64 days]
Atorvastatin Apparent volume of distribution at steady state (Vd,ss/F) after DWC202201 multiple dosing
Time frame: [Time Frame: up to 64 days]
Atorvastatin active metabolite Area under the plasma concentration versus time curve at steady state (AUCinf, ss) after DWC202201 multiple dosing
Time frame: [Time Frame: up to 64 days]
Atorvastatin active metabolite Terminal Half-life at steady state (T1/2,ss) after DWC202201 multiple dosing
Time frame: [Time Frame: up to 64 days]
Atorvastatin active metabolite An estimate of the total body clearance at steady state (CL ss/F) after DWC202201 multiple dosing
Time frame: [Time Frame: up to 64 days]
Atorvastatin active metabolite Apparent volume of distribution at steady state (Vd,ss/F) after DWC202201 multiple dosing
Time frame: [Time Frame: up to 64 days]
Atorvastatin active metabolite metabolic ratio after DWC202201 multiple dosing
Time frame: [Time Frame: up to 64 days]
Fexuprazan Peak Plasma Concentration (Cmax) after DWP14012 single dosing
Time frame: [Time Frame: up to 64 days]
Fexuprazan Area under the plasma drug concentration-time curve from 0 to tau (AUCtau) after DWP14012 single dosing
Time frame: [Time Frame: up to 64 days]
Fexuprazan Area under the plasma drug concentration-time curve from 0 to infinity(AUCinf) after DWP14012 single dosing
Time frame: [Time Frame: up to 64 days]
Fexuprazan The time of peak concentration (Tmax) after DWP14012 single dosing
Time frame: [Time Frame: up to 64 days]
Fexuprazan Terminal Half-life (t1/2) after DWP14012 single dosing
Time frame: [Time Frame: up to 64 days]
Fexuprazan Apparent Clearance (CL/F) after DWP14012 single dosing
Time frame: [Time Frame: up to 64 days]
Fexuprazan Apparent Volume of Distribution After extravascular administration (Vd/F) after DWP14012 single dosing
Time frame: [Time Frame: up to 64 days]
Fexuprazan Peak Plasma Concentration at steady state (Cmax,ss) after DWP14012 multiple dosing
Time frame: [Time Frame: up to 64 days]
Fexuprazan Area under the plasma drug concentration-time curve from 0 to tau at steady state (AUCtau,ss) after DWP14012 multiple dosing
Time frame: [Time Frame: up to 64 days]
Fexuprazan Area under the plasma drug concentration-time curve from 0 to infinity at steady state (AUCinf,ss) after DWP14012 multiple dosing
Time frame: [Time Frame: up to 64 days]
Fexuprazan Time of Maximum Concentration at steady state (Tmax,ss) after DWP14012 multiple dosing
Time frame: [Time Frame: up to 64 days]
Fexuprazan Terminal Half-life at steady state (t1/2,ss) after DWP14012 multiple dosing
Time frame: [Time Frame: up to 64 days]
Fexuprazan An estimate of the total body clearance at steady state (CL ss/F) after DWP14012 multiple dosing
Time frame: [Time Frame: up to 64 days]
Fexuprazan Aapparent volume of distribution after extravascular administration at steady state (Vd,ss/F) after DWP14012 multiple dosing
Time frame: [Time Frame: up to 64 days]
Fexuprazan Accumulation ratio after DWP14012 multiple dosing
Time frame: [Time Frame: up to 64 days]
Fexuprazan active metabolite Peak Plasma Concentration (Cmax) after single dosing
Time frame: [Time Frame: up to 64 days]
Fexuprazan active metabolite Area under the plasma drug concentration-time curve from 0 to tau (AUCtau) after single dosing
Time frame: [Time Frame: up to 64 days]
Fexuprazan active metabolite Area under the plasma concentration extrapolated to infinity (AUCinf) after single dosing
Time frame: [Time Frame: up to 64 days]
Fexuprazan active metabolite The time of peak concentration (Tmax) after single dosing
Time frame: [Time Frame: up to 64 days]
Fexuprazan active metabolite metabolic ratio after single dosing
Time frame: [Time Frame: up to 64 days]
Fexuprazan active metabolite Peak Plasma Concentration at steady state (Cmax,ss) after multiple dosing
Time frame: [Time Frame: up to 64 days]
Fexuprazan active metabolite AUCtau,ss AUCinf,ss Tmax,ss metabolic ratio
Time frame: [Time Frame: up to 64 days]
Fexuprazan active metabolite Area under the plasma drug concentration-time curve from 0 to tau at steady state (AUCtau,ss) after multiple dosing
Time frame: [Time Frame: up to 64 days]
Fexuprazan active metabolite Area under the plasma concentration extrapolated to infinity at steady state (AUCinf,ss) after multiple dosing
Time frame: [Time Frame: up to 64 days]
Fexuprazan active metabolite The time of peak concentration at steady state (Tmax,ss) after multiple dosing
Time frame: [Time Frame: up to 64 days]
Fexuprazan active metabolite metabolic ratio after multiple dosing
Time frame: [Time Frame: up to 64 days]
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Oct 2022 to primary completion in Mar 2023, 5 months.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fexuprazan
Daewoong Pharmaceutical Co. LTD. →